Pediatric expert consensus on the application of glucocorticoids in Kawasaki disease.
10.7499/j.issn.1008-8830.2112033
- Collective Name:Shaanxi Provincial Diagnosis and Treatment Center of Kawasaki Disease/Children's Hospital of Shaanxi Provincial People's Hospital;Beijing Children's Hospital, Capital Medical University;Shanghai Children's Medical Center;Children's Hospital of Shanghai Jiao Tong University;Xianyang Children's Hospital of Shaanxi Province;Suzhou Children's Hospital, Suzhou University;Children's Hospital of Chongqing Medical University;Expert Committee of Advanced Training for Pediatrician, China Maternal and Children's Health Association;Editorial Board of Chinese Journal of Contemporary Pediatrics
- Publication Type:Journal Article
- Keywords:
Child;
Expert consensus;
Glucocorticoid;
Kawasaki disease
- MeSH:
Child;
Child, Preschool;
Consensus;
Coronary Aneurysm;
Glucocorticoids/therapeutic use*;
Humans;
Immunoglobulins, Intravenous;
Mucocutaneous Lymph Node Syndrome/drug therapy*
- From:
Chinese Journal of Contemporary Pediatrics
2022;24(3):225-231
- CountryChina
- Language:English
-
Abstract:
Kawasaki disease (KD) is one of the common acquired heart diseases in under-5-year-old children and is an acute self-limiting vasculitis. After nearly 60 years of research, intravenous immunoglobulin combined with oral aspirin has become the first-line treatment for preventing coronary artery aneurysm in the acute stage of KD. However, glucocorticoid (GC), infliximab, and other immunosuppressants are options for the treatment of KD patients with a high risk of coronary artery aneurysm, no response to intravenous immunoglobulin and a confirmed diagnosis of coronary artery aneurysm. At present, there are still controversies over the use of GC in the treatment of KD. With reference to the latest research findings of KD treatment in China and overseas, this consensus invited domestic pediatric experts to fully discuss and put forward recommendations on the indications, dosage, and usage of GC in the first-line and second-line treatment of KD.
